EUVIMEDEUVIMED entdecken
Crossref

DMOG protects against murine IL-33-induced pulmonary type 2 inflammation through HIF-1 pathway in innate lymphoid cells

Anupriya Gupta, Chang Ook Park, Kwonik Oh

Biochemical and Biophysical Research Communications · 2023

DOI: 10.1016/j.bbrc.2023.149139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Anupriya Gupta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Hallym University College of Medicine, Chuncheon, South Korea. Hauptthemen laut MEDLINE: Pneumonia, Hypersensitivity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Hallym University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One of the traditional methods of treating allergy is to avoid the allergen, protocol that has long been used in high altitude clinics. It has been hypothesized that the therapeutic effect of high altitude on allergy is due to allergen avoidance, exposure to sunlight and reduced stress. However, the contribution of environmental elements like low oxygen pressure and hypoxia remains underexplored. In this study, we examined the role of hypoxia in the development of type 2 lung inflammation. Mice were administered with papain or recombinant IL-33 intra-nasally to induce type 2 lung inflammation. Some of them were treated additionally with the prolyl hydroxylase (PHD) inhibitor DMOG, which mimics hypoxia. DMOG treatment exhibited an inhibitory effect on the lung inflammation induced by papain or IL-33, operating in a manner independent of T and B cells. The anti-inflammatory effect of DMOG was accompanied by a downregulation of IL-5 and IL-13 in innate lymphoid cells (ILCs), which was abolished in HIF-1α deficient mice. Collectively, our findings suggest that DMOG's modulatory effect on IL-5 and IL-13 operates through the HIF-1 pathway, resulting in a reduction in type 2 lung inflammation. These findings underscore the role of the PHD-HIF pathway in IL-5 and IL-13 expression in lung ILCs and pharmacological inhibition of PHD might be a novel therapeutic candidate for type 2 lung inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PneumoniaHypersensitivityMiceAnimalsInterleukin-13Interleukin-33Immunity, InnateInterleukin-5PapainLymphocytesHypoxiaAllergensInflammationHypoxia-Inducible Factor 1, alpha Subunit

Stichwörter der Autor:innen

DMOGHypoxiaIL-13IL-5Lung inflammation

Substanzen

Interleukin-13Interleukin-33Interleukin-5PapainAllergensHypoxia-Inducible Factor 1, alpha Subunit

Autor:innen und Institutionen

  • Department of Pathology, Hallym University College of Medicine, Chuncheon, South Korea.
  • Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Pathology, Hallym University College of Medicine, Chuncheon, South Korea; Institute of Medical Science, Hallym University College of Medicine, Chuncheon, South Korea. Electronic address: kwonik@hallym.ac.k…

Förderung

  • Hallym University

Zitieren

APA

Gupta, A., Park, C. O., & Oh, K. (2023). DMOG protects against murine IL-33-induced pulmonary type 2 inflammation through HIF-1 pathway in innate lymphoid cells. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.149139

Vancouver

Gupta A, Park CO, Oh K. DMOG protects against murine IL-33-induced pulmonary type 2 inflammation through HIF-1 pathway in innate lymphoid cells. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.149139

BibTeX
@article{Gupta2023,
  author = {Gupta, Anupriya and Park, Chang Ook and Oh, Kwonik},
  title = {DMOG protects against murine IL-33-induced pulmonary type 2 inflammation through HIF-1 pathway in innate lymphoid cells},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2023},
  doi = {10.1016/j.bbrc.2023.149139}
}
Kostenlos starten →